Publications - Curtana Pharmaceuticals

Links on this page will lead you to another website. These links are for informational purposes only; Curtana Pharmaceuticals assumes no responsibility for the content outside our website.

Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179
Li, Y., Lim, C., Dismuke, T. et al.
Nat Commun 16, 1091 (2025).
OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma
Desai, K., Wanggou, S., Luis, E. et al.
Nat Commun 16, 1092 (2025).
Fitness Screens Map State-Specific Glioblastoma Stem Cell Vulnerabilities
Graham MacLeod, Fatemeh Molaei, Shahan Haider, Maira P. Almeida, Sichun Lin, Michelle Kushida, Haresh Sureshkumar, Jasmine K. Bhatti, Jack Q. Lu, Daniel Schramek, Peter B. Dirks, Stephane Angers
Cancer Res 1 December 2024; 84 (23): 3967–3983.
Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration
Myers, B.L., Brayer, K.J., Paez-Beltran, L.E. et al.
Nat Commun 15, 10363 (2024).
Biological functions of the Olig gene family in brain cancer and therapeutic targeting
Szu JI, Tsigelny IF, Wojcinski A, Kesari S.
Front Neurosci. 2023 May 18;17:1129434.
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Zhenhua Xu, Najiba Murad, Daniel Malawsky, Ran Tao, Samuel Rivero-Hinojosa, Dörthe Holdhof, Ulrich Schüller, Peng Zhang, Christopher Lazarski, Brian R. Rood, Roger Packer, Timothy Gershon, Yanxin Pei;
Clin Cancer Res 1 October 2022; 28 (19): 4278–4291.
Novel Small Molecule Inhibitors Of The OLIG2 Transcription Factor: Promising New Therapeutics For Glioblastoma
Alton, G., & Kesari, S.
Future Oncology (London, England), 2016:12(8), 1001–4.
Multiple Spatially Related Pharmacophores Define Small Molecule Inhibitors of OLIG2 in Glioblastoma
Tsigelny, I. F., Mukthavaram, R., Kouznetsova, V. L., Chao, Y., Babic, I., Nurmemmedov, E., … Kesari, S. (2015).
Oncotarget, Oct 30(Online). doi:10.18632/oncotarget.5633
Antagonistic Modulation of Gliomagenesis by Pax6 And OLIG2 in PDGF-Induced Oligodendroglioma
Appolloni I, Calzolari F, Barilari M, Terrile M, Daga A, Malatesta P.
International Journal Of Cancer (Journal International du Cancer). 2012;131(7):E1078–87.
The Central Nervous System-Restricted Transcription Factor OLIG2 Opposes P53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma
Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta J a, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD.
Cancer cell. 2011;19(3):359–71.
Malignant Gliomas in Adults
Wen PY, Kesari S.
The New England journal of medicine. 2008;359(5):492–507.
OLIG2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma
Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta J a, Bachoo RM, Kane M, Louis DN, Depinho R a, Anderson DJ, Stiles CD, Rowitch DH.
Neuron. 2007;53(4):503–17.
The Oligodendroglial Lineage Marker OLIG2 is Universally Expressed in Diffuse Gliomas
Ligon KL, Alberta J a, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH.
Journal of neuropathology and experimental neurology. 2004;63(5):499–509.